Back to search

Article

Incident Frailty and Mortality Risk with Significant Tirzepatide-Associated Weight Loss in Medicare-Age Patients

2026-07-13

Abstract excerpt

The U.S. Medicare GLP-1 Bridge program and existing Part D pathways are expanding access to tirzepatide therapy for older adults, including Zepbound through the Bridge for weight management and Mounjaro through Part D coverage for type 2 diabetes. This necessitates identification of clinical vulnerabilities in geriatric patients that may emerge during pharmacologic weight loss. Here we evaluated incident malnutrit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cc85b96d-8052-5d9a-9fbd-6e075dcb5354
DOI
10.20944/preprints202607.0809.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Incident Frailty and Mortality Risk with Significant Tirzepatide-Associated Weight Loss in Medicare-Age PatientsDOI 10.20944/preprints202607.0809.v1
Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotypingSemantic proximity
Greater lean-body-mass decline with tirzepatide than semaglutide in routine care, revealed by body-composition digital phenotypingSemantic proximity
A Randomized Clinical Trial of Metformin to Reduce Frailty in Older Adults with Glucose IntoleranceSemantic proximity
Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan.Semantic proximity
Metabolic Characteristics of Frail Older People with Diabetes Mellitus—A Systematic Search for PhenotypesSemantic proximity
The Effect of Frailty on Body Composition and Its Impact on the Use of SGLT-2 Inhibitors and GLP-1RA in Older People with DiabetesSemantic proximity
Association of metabolomic aging acceleration and body mass index phenotypes with mortality and obesity-related morbidities.Semantic proximity
Hypoglycaemic therapy in frail older people with type 2 diabetes mellitus-a choice determined by metabolic phenotype.Semantic proximity
From one-size-fits-all to phenotype-based pharmacotherapy: How far are we in obesity management?Semantic proximity
Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight lossSemantic proximity
Gender-specific Association of Frailty, Polypharmacy, and the Five-year Mortality Risk: A Real-world Retrospective StudySemantic proximity
Optimized nutritional management mitigates short-term muscle mass loss in elderly frail patients with COVID-19: a randomized controlled trialSemantic proximity
Select a neighboring publication to make it the new centre.